Sign in to view content

It’s the Patient, Not the Agent: An Assessment of Anti-VEGF Extended Dosing Intervals in Patients With nAMD

David A. Eichenbaum, MD, FASRS

Video
Published 2019

Related

A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD
Vrinda S. Hershberger, MD, PhD
On Demand Cases, Courses, and Papers
2021
Higher Order OCT Feature Assessment of the Impact of Fluid Dynamics on Visual Acuity in Neovascular AMD in a Phase III Clinical Trial: The Importance of Outer Retinal Integrity
Justis P. Ehlers, MD, FASRS
Annual Meeting Talks
2022
Safety and Efficacy of CRISPR-Based Genome Editing for Neovascular AMD
Glenn C. Yiu, MD, PhD
Annual Meeting Talks
2023

Category: AMD-Neovascular

See more